Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

Blood - 3 Apr 2014

Guglielmelli Paola, Biamonte Flavia, Rotunno Giada, Artusi Valentina, Artuso Lucia, Bernardis Isabella, Tenedini Elena, Pieri Lisa, Paoli Chiara, Mannarelli Carmela, Fjerza Rajmonda, Rumi Elisa, Stalbovskaya Viktoriya, Squires Matthew, Cazzola Mario, Manfredini Rossella, Harrison Claire, Tagliafico Enrico, Vannucchi Alessandro M

Abstract excerpt

The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein
Share to Janus Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Polycomb Repressive Complex 2

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Ribonucleoproteins

Share to Serine-Arginine Splicing Factors

Source

Identifiers

PMID: 24458439
DOI: 10.1182/blood-2013-11-536557

Genes

JAK2
ASXL1
IDH1
JAK1
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24458439-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.PMID 24458439Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Semantic proximity Read ↗

[Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Semantic proximity Read ↗

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Semantic proximity Read ↗

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.Semantic proximity Read ↗

Efficacy of ruxolitinib for myelofibrosis.Semantic proximity Read ↗

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Semantic proximity Read ↗

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaSemantic proximity Read ↗

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.